- Home
- CGEM vs NCDL Comparison
CGEM vs NCDL Comparison
Compare CGEM & NCDL Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
- Machine Learning Prediction
- ML Decision
- CGEM
- NCDL
- Stock Information
- Founded
- CGEM 2016
- NCDL 2019
- Country
- CGEM United States
- NCDL United States
- Employees
- CGEM N/A
- NCDL N/A
- Industry
- CGEM Biotechnology: Pharmaceutical Preparations
- NCDL
- Sector
- CGEM Health Care
- NCDL
- Exchange
- CGEM Nasdaq
- NCDL NYSE
- Market Cap
- CGEM 530.0M
- NCDL 814.1M
- IPO Year
- CGEM 2021
- NCDL N/A
- Fundamental
- Price
- CGEM $7.45
- NCDL $16.84
- Analyst Decision
- CGEM Strong Buy
- NCDL Hold
- Analyst Count
- CGEM 6
- NCDL 4
- Target Price
- CGEM $28.17
- NCDL $16.31
- AVG Volume (30 Days)
- CGEM 349.8K
- NCDL 266.1K
- Earning Date
- CGEM 08-07-2025
- NCDL 08-06-2025
- Dividend Yield
- CGEM N/A
- NCDL 12.45%
- EPS Growth
- CGEM N/A
- NCDL N/A
- EPS
- CGEM N/A
- NCDL N/A
- Revenue
- CGEM N/A
- NCDL N/A
- Revenue This Year
- CGEM N/A
- NCDL N/A
- Revenue Next Year
- CGEM N/A
- NCDL N/A
- P/E Ratio
- CGEM N/A
- NCDL N/A
- Revenue Growth
- CGEM N/A
- NCDL N/A
- 52 Week Low
- CGEM $6.85
- NCDL $14.21
- 52 Week High
- CGEM $21.01
- NCDL $18.01
- Technical
- Relative Strength Index (RSI)
- CGEM 41.65
- NCDL 58.55
- Support Level
- CGEM $7.29
- NCDL $16.42
- Resistance Level
- CGEM $7.94
- NCDL $17.17
- Average True Range (ATR)
- CGEM 0.41
- NCDL 0.27
- MACD
- CGEM -0.00
- NCDL 0.04
- Stochastic Oscillator
- CGEM 21.31
- NCDL 72.03
About CGEM Cullinan Oncology Inc.
Cullinan Therapeutics Inc is a biopharmaceutical company. It has a diversified portfolio of clinical-stage assets that inhibit key drivers of disease or harness the immune system to eliminate diseased cells in both oncology and autoimmune diseases. Its understanding of oncology, immunology, and translational medicine, creates differentiated ideas, identifies the appropriate targets, and selects the optimal modality to develop transformative therapeutics across a variety of cancer and autoimmune indications. It has one reporting and one operating segment, which is the business of developing immunology and oncology therapies.
About NCDL NUVEEN CHURCHILL DIRECT LENDNG CORP
Nuveen Churchill Direct Lending Corp is a specialty finance company focused predominantly on investing in senior secured loans to private equity-owned U.S. middle market companies. It invest in senior secured loans that typically pay floating interest rates and are senior in the capital structure to junior debt and equity.